Westfield Capital Management
AEGR

Westfield Capital Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Westfield Capital Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,323,633
Closed -$60.8M – 324
2015
Q1 		$60.8M Sell
2,323,633
-432,300
-16% -$11M 0.35% 100
2014
Q4 		$57.7M Sell
2,755,933
-719,373
-21% -$18.1M 0.34% 100
2014
Q3 		$116M Buy
3,475,306
+267,708
+8% +$8.31M 0.71% 40
2014
Q2 		$103M Buy
3,207,598
+1,491,243
+87% +$55.5M 0.61% 53
2014
Q1 		$79.3M Buy
+1,716,355
New +$101M 0.47% 74

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Westfield Capital Management's AEGR Position: Q2 2015 in Review

Westfield Capital Management sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2015, closing a stake of 2,323,633 shares — an estimated $60.8M sold.

Westfield Capital Management first reported a position in AEGR in Q1 2014 and held it in 5 quarters. The position peaked at $116M in Q3 2014. 97 funds tracked by Wall St. Rank hold AEGR as of Q2 2015.

  • Westfield Capital Management reported no remaining Aegerion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Westfield Capital Management sold 2,323,633 Aegerion Pharmaceuticals shares in Q2 2015, an estimated $60.8M.
  • Westfield Capital Management first reported a position in Aegerion Pharmaceuticals in Q1 2014 and held it in 5 quarters.
  • Westfield Capital Management's Aegerion Pharmaceuticals position peaked at $116M in Q3 2014.
  • 97 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2015.

Based on Westfield Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.